Freitas J E, Gross M D, Ripley S, Shapiro B
Semin Nucl Med. 1985 Apr;15(2):106-31. doi: 10.1016/s0001-2998(85)80021-0.
Thyroid cancer is uncommon, with an incidence of 10,300 new patients each year and a mortality of 1,100 patients each year. Patient survival correlates with many factors, including tumor pathology, age, primary lesion size, distant metastases, extent of surgery, and radioiodine therapy. Deaths from thyroid cancer may occur many years after diagnosis, and such an indolent course has hampered the analysis of the multiple treatment programs advocated. Thyroid imaging continues to play an important role in the initial detection and follow-up management of thyroid cancer, but the search for a specific tracer for the primary lesion continues. The complementary role of serum thyroglobulin and radioiodine in the follow-up of the thyroidectomized patient is discussed. Radioiodine therapy has proven effectiveness in those patients with radioiodine-avid distant metastases and/or regional metastases. Whether radioiodine ablation of residual thyroid bed activity is beneficial remains controversial.
甲状腺癌并不常见，每年有10300例新发病例，每年有1100例死亡病例。患者的生存率与许多因素相关，包括肿瘤病理、年龄、原发灶大小、远处转移、手术范围以及放射性碘治疗。甲状腺癌导致的死亡可能在诊断多年后发生，这种惰性病程阻碍了对所倡导的多种治疗方案的分析。甲状腺成像在甲状腺癌的初始检测和后续管理中继续发挥重要作用，但仍在寻找针对原发灶的特异性示踪剂。本文讨论了血清甲状腺球蛋白和放射性碘在甲状腺切除患者随访中的互补作用。放射性碘治疗已被证明对那些有放射性碘摄取性远处转移和/或区域转移的患者有效。残留甲状腺床活性的放射性碘消融是否有益仍存在争议。
